12 Based on current cardiovascular outcome data such as that provided in SUSTAIN-6, the American Diabetes Association (ADA) now recommends GLP-1 receptor agonists with proven cardiovascular benefit as a preferred option for second-line add-on therapy in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) following metformin and lifestyle-change intensification
*In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly via subcutaneous injection, the FDA-approved formulation later marketed under the brand name Wegovy for chronic weight management in adults with obesity or overweight and at least one weight-related condition
Overexpression of PDGFR has been observed in VS [74, 80, 81], and PDGFR inhibitors including AG1296, imatinib, and nilotinib are effective in preventing PDGFR-driven proliferation when tested in VS in vitro models [74, 82]
Skin density measurable changes have been documented in clinical trials by this window 13
En otros casos no se perciben cambios claros, especialmente si no existe una necesidad especfica o si el periodo de uso es breve